IDEXX Laboratories, Inc. $IDXX Shares Purchased by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 97.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,354 shares of the company’s stock after purchasing an additional 1,163 shares during the period. Sax Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $1,323,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at about $26,000. SHP Wealth Management bought a new position in IDEXX Laboratories in the 4th quarter valued at about $26,000. Elevation Wealth Partners LLC grew its position in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares in the last quarter. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $30,000. Finally, Arlington Trust Co LLC increased its position in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares during the period. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on IDXX. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group lifted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $756.00.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $586.67 on Monday. The stock’s 50 day simple moving average is $559.73 and its 200 day simple moving average is $584.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company has a market capitalization of $46.22 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 3.18 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.82 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.